14 December 2023
14 December 2023
Ironwood Pharmaceuticals completed an acquisition of the gastrointestinal disease company VectivBio.
Odronextamab has demonstrated clinically meaningful efficacy and safety in patients with R/R FL and DLBCL.
The US National Institutes of Health created KYV-101 to boost tolerability and for assessment in a Phase I oncology trial in 20 subjects.
An international Phase III clinical trial of the treatment is underway in TGCT patients in the US, Europe, China and Canada.
The company filed the BLA based on findings from the Phase II DeLLphi-301 trial of tarlatamab in SCLC patients.
Daiichi Sankyo plans to leverage the French startup’s technology to develop its RNA-targeted therapeutics pipeline.
The company will use the proceeds to progress the clinical development of its lead drug candidate.
What are the technology themes keeping senior executives up at night? And what are their investment priorities for 2024?
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials.
Give your business an edge with our leading industry insights.
